NASDAQ:ADVM - Adverum Biotechnologies Stock Price, News & Analysis

$10.62
-0.37 (-3.37 %)
(As of 08/23/2019 01:24 PM ET)
Today's Range
$10.59
Now: $10.62
$11.2527
50-Day Range
$11.16
MA: $13.16
$16.01
52-Week Range
$2.62
Now: $10.62
$16.38
Volume570,729 shs
Average Volume1.13 million shs
Market Capitalization$684.57 million
P/E RatioN/A
Dividend YieldN/A
Beta2.42
Adverum Biotechnologies, Inc, a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADVM
CUSIPN/A
Phone650-272-6269

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.61 million
Book Value$2.76 per share

Profitability

Net Income$-72,630,000.00
Net Margins-4,505.40%

Miscellaneous

Employees82
Market Cap$684.57 million
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable

Receive ADVM News and Ratings via Email

Sign-up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.


Adverum Biotechnologies (NASDAQ:ADVM) Frequently Asked Questions

What is Adverum Biotechnologies' stock symbol?

Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies Inc (NASDAQ:ADVM) issued its quarterly earnings data on Thursday, August, 8th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.31) by $0.08. Adverum Biotechnologies had a negative net margin of 4,505.40% and a negative return on equity of 31.21%. View Adverum Biotechnologies' Earnings History.

When is Adverum Biotechnologies' next earnings date?

Adverum Biotechnologies is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Adverum Biotechnologies.

What price target have analysts set for ADVM?

6 brokerages have issued twelve-month target prices for Adverum Biotechnologies' shares. Their predictions range from $4.00 to $12.00. On average, they expect Adverum Biotechnologies' stock price to reach $9.50 in the next twelve months. This suggests that the stock has a possible downside of 10.5%. View Analyst Price Targets for Adverum Biotechnologies.

What is the consensus analysts' recommendation for Adverum Biotechnologies?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Adverum Biotechnologies.

What are Wall Street analysts saying about Adverum Biotechnologies stock?

Here are some recent quotes from research analysts about Adverum Biotechnologies stock:
  • 1. According to Zacks Investment Research, "Adverum Biotechnologies, Inc. is a gene therapy company. The Company discovers and develops novel medicines for patients living with rare diseases. Adverum Biotechnologies Inc, formerly known as Avalanche Biotechnologies Inc., is headquartered in Menlo Park, California. " (7/30/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We are downgrading and reducing our 12-month PT to $4 from $12. The new PT is solely based on the ADVM-022 wAMD program, soon to enter P1 testing in 2018. Our changed perspective results from the PR Friday that the company discontinued development of lead asset ADVM-043 for treatment of A1AT deficiency and hit pause on the preclinical HAE program, deciding not to file an IND in 4Q18. Although further clarity on rare disease programs is expected in 1H19, we now see only the wAMD program as a potential driver of value over the next ~12-18 months." (11/4/2018)

Has Adverum Biotechnologies been receiving favorable news coverage?

Media headlines about ADVM stock have been trending positive on Friday, according to InfoTrie. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Adverum Biotechnologies earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the next few days. View News Stories for Adverum Biotechnologies.

Who are some of Adverum Biotechnologies' key competitors?

What other stocks do shareholders of Adverum Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), CA (CA), BlackRock (BLK), Endologix (ELGX), Aegean Marine Petroleum Network (ANW), Immunomedics (IMMU), Nextera Energy Partners (NEP), Chipotle Mexican Grill (CMG) and Buckeye Partners (BPL).

Who are Adverum Biotechnologies' key executives?

Adverum Biotechnologies' management team includes the folowing people:
  • Dr. Mehdi Gasmi, Pres & Chief Scientific Officer (Age 52)
  • Dr. Mitchell H. Finer, Co-Founder & Director (Age 60)
  • Dr. Amber Salzman, Consultant (Age 57)
  • Ms. Leone D. Patterson, CEO & Director (Age 56)
  • Mr. Thomas Leung, Chief Financial Officer

Who are Adverum Biotechnologies' major shareholders?

Adverum Biotechnologies' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.67%), Renaissance Technologies LLC (6.05%), UBS Group AG (4.87%), JPMorgan Chase & Co. (4.14%), Vanguard Group Inc. (3.92%) and Orbimed Advisors LLC (3.04%). View Institutional Ownership Trends for Adverum Biotechnologies.

Which major investors are selling Adverum Biotechnologies stock?

ADVM stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., WS Management Lllp, BlackRock Inc., Morgan Stanley, Victory Capital Management Inc., Jacobs Levy Equity Management Inc., BNP Paribas Arbitrage SA and AQR Capital Management LLC. View Insider Buying and Selling for Adverum Biotechnologies.

Which major investors are buying Adverum Biotechnologies stock?

ADVM stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, Orbimed Advisors LLC, Price T Rowe Associates Inc. MD, Vanguard Group Inc., Atika Capital Management LLC, Invesco Ltd., Nuveen Asset Management LLC and D. E. Shaw & Co. Inc.. View Insider Buying and Selling for Adverum Biotechnologies.

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adverum Biotechnologies' stock price today?

One share of ADVM stock can currently be purchased for approximately $10.62.

How big of a company is Adverum Biotechnologies?

Adverum Biotechnologies has a market capitalization of $684.57 million and generates $1.61 million in revenue each year. The biotechnology company earns $-72,630,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. Adverum Biotechnologies employs 82 workers across the globe.View Additional Information About Adverum Biotechnologies.

What is Adverum Biotechnologies' official website?

The official website for Adverum Biotechnologies is http://www.adverum.com/.

How can I contact Adverum Biotechnologies?

Adverum Biotechnologies' mailing address is 1035 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-272-6269 or via email at [email protected]


MarketBeat Community Rating for Adverum Biotechnologies (NASDAQ ADVM)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  267 (Vote Outperform)
Underperform Votes:  278 (Vote Underperform)
Total Votes:  545
MarketBeat's community ratings are surveys of what our community members think about Adverum Biotechnologies and other stocks. Vote "Outperform" if you believe ADVM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADVM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel